Amicas agrees to Thoma Bravo buyout
This article was originally published in The Gray Sheet
Executive Summary
Private equity investment firm Thoma Bravo will acquire medical imaging IT firm Amicas for $217 million under a definitive agreement announced Dec. 28. Thoma Bravo will pay $5.35 per share for the company - a 21% premium over its Dec. 24 stock price close of $4.42. "With the additional capital and operational expertise available to Amicas through Thoma Bravo, we will be able to grow as the needs of our customers evolve and will be enabled to better serve our market," said Amicas CEO Stephen Kahane. Amicas, which makes picture archiving and communication systems and other medical imaging IT solutions, notes that it has 45 days to solicit potential alternative proposals under the agreement
You may also be interested in...
Amicas weighs Merge Healthcare takeover bid
Imaging IT solutions provider Amicas' board of directors pledges to consider an updated $248 million acquisition proposal from health IT firm Merge Healthcare as an alternative to Amicas' December agreement to be acquired for $217 million by private equity investment firm Thoma Bravo (1"The Gray Sheet" Jan. 4, 2010). While Amicas had initially dismissed Merge Healthcare's alternative offer as "highly conditional, illusory and risky," an update to the offer announced Feb. 24 included "an executed definitive commitment letter for $200 million of financing from Morgan Stanley," Amicas states. Amicas' board will now "evaluate the updated Merge proposal to determine appropriate next steps," the company said Feb. 24
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.